Search
Femasys Inc
FEMYAdd to Watchlist
2.580USD
+0.020+0.78%
Close 09-22 16:00（ET）
7.79MMarket Cap
LossP/E TTM
About Femasys Inc Company
Femasys Inc. is a biomedical company. The Company is focused on addressing the unmet needs of women worldwide with a broad portfolio of in-office, accessible, and therapeutic and diagnostic solutions. The Company has two lead product candidates: FemBloc and FemaSeed. FemBloc is a permanent birth control solution in development. Its permanent birth control solution in development includes its FemBloc system, which features dual intrauterine directional delivery targeting both fallopian tubes with a degradable blended biopolymer. FemaSeed is an artificial insemination infertility treatment. Its artificial insemination solution in development includes its FemaSeed product candidate for artificial insemination, which features single intrauterine directional delivery. It also developed FemCerv, which is an endocervical tissue sampler for cervical cancer diagnosis; FemVue, which is a companion diagnostic for fallopian tube assessment; FemCath, which is an intrauterine catheter, and FemChec.
Femasys Inc Profile
Ticker SymbolFEMY
Company nameFemasys Inc
IPO dateJun 18, 2021
CEOLee-Sepsick (Kathy)
Number of employees69
Security typeOrdinary Share
Fiscal year-endJun 18
Address3950 Johns Creek Court
CitySUWANEE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code30024
Phone17705003910
Websitehttps://www.femasys.com/
Ticker SymbolFEMY
IPO dateJun 18, 2021
CEOLee-Sepsick (Kathy)
Company Executives of Femasys Inc
Name
Name/Position
Position
Shareholding
Change
Ms. Kathy Lee-Sepsick
Ms. Kathy Lee-Sepsick
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
37.27K
+41.93%
Ms. Kathy Lee-Sepsick
Ms. Kathy Lee-Sepsick
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
37.27K
+41.93%
Mr. John Canning
Mr. John Canning
Chief Operating Officer
Chief Operating Officer
5.88K
+74.47%
Mr. John Canning
Mr. John Canning
Chief Operating Officer
Chief Operating Officer
5.88K
+74.47%
Dr. Kenneth D. Eichenbaum, M.D.
Dr. Kenneth D. Eichenbaum, M.D.
Independent Director
Independent Director
1.25K
--
Dr. Kenneth D. Eichenbaum, M.D.
Dr. Kenneth D. Eichenbaum, M.D.
Independent Director
Independent Director
1.25K
--
Ms. Kelley Nicholas
Ms. Kelley Nicholas
Chief Commercial Officer
Chief Commercial Officer
4.00
--
Ms. Kelley Nicholas
Ms. Kelley Nicholas
Chief Commercial Officer
Chief Commercial Officer
4.00
--
Mr. Charles E. Larsen
Mr. Charles E. Larsen
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. Edward Uzialko, Jr.
Mr. Edward Uzialko, Jr.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Ms. Kathy Lee-Sepsick
Ms. Kathy Lee-Sepsick
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
37.27K
+41.93%
Ms. Kathy Lee-Sepsick
Ms. Kathy Lee-Sepsick
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
37.27K
+41.93%
Mr. John Canning
Mr. John Canning
Chief Operating Officer
Chief Operating Officer
5.88K
+74.47%
Mr. John Canning
Mr. John Canning
Chief Operating Officer
Chief Operating Officer
5.88K
+74.47%
Dr. Kenneth D. Eichenbaum, M.D.
Dr. Kenneth D. Eichenbaum, M.D.
Independent Director
Independent Director
1.25K
--
Dr. Kenneth D. Eichenbaum, M.D.
Dr. Kenneth D. Eichenbaum, M.D.
Independent Director
Independent Director
1.25K
--
FAQs
Who are the top five shareholders of Femasys Inc?
The top five shareholders of Femasys Inc are: Ms. Kathy Lee-Sepsick
How many institutions hold shares of Femasys Inc (FEMY)?
As of 2026Q1, 64 institutions hold shares of Femasys Inc, with a combined market value of approximately 6.18M, accounting for 10.23% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 1191594.00.